bazedoxifene has been researched along with loperamide in 1 studies
| Studies (bazedoxifene) | Trials (bazedoxifene) | Recent Studies (post-2010) (bazedoxifene) | Studies (loperamide) | Trials (loperamide) | Recent Studies (post-2010) (loperamide) |
|---|---|---|---|---|---|
| 307 | 69 | 249 | 1,358 | 196 | 488 |
| Protein | Taxonomy | bazedoxifene (IC50) | loperamide (IC50) |
|---|---|---|---|
| Cocaine esterase | Homo sapiens (human) | 5.7 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.005 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.5 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.27 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.081 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.202 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0014 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.337 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.896 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 3.125 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 4.105 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.033 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.239 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.628 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
1 other study(ies) available for bazedoxifene and loperamide
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |